Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody https://clinicaltrials.gov/ct2/show/NCT02142218
So this will require, like the Merck program, that you first must fail IPI and BRAF drugs is you are positive. It does not allow prior PD1 of any kind. It is rolling out with a conservative estimate of 14 days. Locations will likely be those that had prior trials. Stay tuned for more on global locations.
Good question, but not what I have heard. The requirement will be for stage IV disease though. These requirements are based on clinical trials that they follow up and to meet unmet need, i.e. you must try the FDA approved drugs and run out of options.
Viewing 6 posts - 1 through 6 (of 6 total)
The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.